Extended Management & Measurement of Autism (Emma): An Open-Label, Follow-On Study to Investigate the Safety and Impact on Developmental Trajectory of 18 Months Treatment With Fluoxetine Orally Dissolving Tablet (Odt) In Childhood and Adolescent Autistic Disorder.

Trial Profile

Extended Management & Measurement of Autism (Emma): An Open-Label, Follow-On Study to Investigate the Safety and Impact on Developmental Trajectory of 18 Months Treatment With Fluoxetine Orally Dissolving Tablet (Odt) In Childhood and Adolescent Autistic Disorder.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2010

At a glance

  • Drugs Fluoxetine (Primary)
  • Indications Pervasive child development disorders
  • Focus Adverse reactions
  • Acronyms EMMA
  • Most Recent Events

    • 24 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Feb 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 11 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top